PRMT5 and neoplasm: For example, MRTX1719, a MTA-cooperative PRMT5 inhibitor currently in Phase I clinical trial, potently inhibited cell growth of MTAP-del HCT116 tumor cells (IC50, 12 nM), but did not show strong inhibition on MTAP-wt HCT116 cells (IC50, 980 nM), generating a selectivity of ~80× (65).